Advanced Biomed Inc. - Common Stock
Advanced Biomed Inc. - Common Stock
Share · US00752P1049 · ADVB (XNAS)
Overview Financial Indicators
0,93 USD
-0,92 % -0,009 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
09.06.2025 19:56

Current Prices from Advanced Biomed Inc. - Common Stock

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
ADVB
USD
09.06.2025 19:56
0,93 USD
0,94 USD
-1,23 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
-0,92 % -6,21 % -12,83 % -75,24 % -75,17 % -75,17 % -75,17 %

Profil de l'entreprise pour Advanced Biomed Inc. - Common Stock Action

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, a fully automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cells (CTCs) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also provides microfluidic biochips comprising A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips that are designed to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include the A+CTCE kit, which is used to identify epithelial circulating tumor cells and is determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; the A+CTCM kit, which is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; the A+EMT, which is used to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and the A+CM, which is used to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.

Données de l'entreprise

Nom Advanced Biomed Inc. - Common Stock
Société Advanced Biomed Inc. Common Stock
Symbole ADVB
Site web https://www.advanbiomed.com
Marché d'origine XNAS NASDAQ
ISIN US00752P1049
Type de titre Action
Secteur Healthcare
Industrie Medical - Diagnostics & Research
PDG Dr. Yi Lu Ph.D.
Capitalisation boursière 42 Mio
Pays États-Unis d'Amérique
Devise USD
Employés 0,0 T
Adresse 122 East 42nd Street, 10168 New York
Date d'introduction en bourse 2025-03-06

Symboles boursiers

Nom Symbole
NASDAQ ADVB

Autres actions

Les investisseurs qui détiennent Advanced Biomed Inc. - Common Stock ont également les actions suivantes dans leur portefeuille :
BPE FINANCE INTERNATIONAL LD ZERO CPN NTS 15/06/28
BPE FINANCE INTERNATIONAL LD ZERO CPN NTS 15/06/28 Obligation
DZ BANK CLN E.9576
DZ BANK CLN E.9576 Obligation
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025